Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 901-907 |
| Number of pages | 7 |
| Journal | Carbohydrate Research |
| Volume | 344 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 12 May 2009 |
Fingerprint
Keywords
- Chitosan derivatives
- hydroxyapatite
- calcium phosphate implants
- calcein
- FITC-dextran
Cite this
}
Chitosan derivatives alter release profiles of model compounds from calcium phosphate implants. / Green, S; Roldo, M; Douroumis, D; Bouropoulos, N; Lamprou, D; Fatouros, D G.
In: Carbohydrate Research, Vol. 344, No. 7, 12.05.2009, p. 901-907.Research output: Contribution to journal › Article
TY - JOUR
T1 - Chitosan derivatives alter release profiles of model compounds from calcium phosphate implants
AU - Green, S
AU - Roldo, M
AU - Douroumis, D
AU - Bouropoulos, N
AU - Lamprou, D
AU - Fatouros, D G
PY - 2009/5/12
Y1 - 2009/5/12
N2 - The aim of the current study was to evaluate the impact of chitosan derivatives, namely N-octyl-chitosan and N-octyl-O-sulfate chitosan, incorporated in calcium phosphate implants to the release profiles of model drugs. The rate and extent of calcein (on M.W. 650 Da) ED, and FITC-dextran (M.W. 40 kDa) on in vitro release were monitored by fluorescence spectroscopy. Results show that calcein release is affected by the type of chitosan derivative used. A higher percentage of model drug was released when the hydrophilic polymer N-octyl-sulfated chitosan was present in the tablets compared with the tablets containing the hydrophobic polymer N-octyl-chitosan. The release profiles of calcein or FD from tablets containing N-octyl-O-sulfate revealed a complete release for FD after 120 h compared with calcein where 20% of the drug was released over the same time period. These results suggest that the difference in the release profiles observed from the implants is dependent on the molecular weight of the model drugs. These data indicate the potential of chitosan derivatives in controlling the release profile of active compounds from calcium phosphate implants.
AB - The aim of the current study was to evaluate the impact of chitosan derivatives, namely N-octyl-chitosan and N-octyl-O-sulfate chitosan, incorporated in calcium phosphate implants to the release profiles of model drugs. The rate and extent of calcein (on M.W. 650 Da) ED, and FITC-dextran (M.W. 40 kDa) on in vitro release were monitored by fluorescence spectroscopy. Results show that calcein release is affected by the type of chitosan derivative used. A higher percentage of model drug was released when the hydrophilic polymer N-octyl-sulfated chitosan was present in the tablets compared with the tablets containing the hydrophobic polymer N-octyl-chitosan. The release profiles of calcein or FD from tablets containing N-octyl-O-sulfate revealed a complete release for FD after 120 h compared with calcein where 20% of the drug was released over the same time period. These results suggest that the difference in the release profiles observed from the implants is dependent on the molecular weight of the model drugs. These data indicate the potential of chitosan derivatives in controlling the release profile of active compounds from calcium phosphate implants.
KW - Chitosan derivatives
KW - hydroxyapatite
KW - calcium phosphate implants
KW - calcein
KW - FITC-dextran
U2 - 10.1016/j.carres.2009.02.022
DO - 10.1016/j.carres.2009.02.022
M3 - Article
VL - 344
SP - 901
EP - 907
JO - Carbohydrate Research
JF - Carbohydrate Research
SN - 0008-6215
IS - 7
ER -